Immune checkpoints hamper anti-tumor immune responses, and the use of antibodies to block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed death 1 (PD-1) pathways – achieving immune checkpoint blockade (ICB) – can enhance anti-tumor immune responses. Here, CTLA4 is linked to neoplasm.